Union Cycliste Internationale
English  |  Français  
Home ▪
Home Road Track Mountain Bike Cyclo-cross BMX Trials Indoor cycling Para-cycling Cycling for all
Official UCI Partners

News
Agrandir le texte Réduire le texte Imprimer la page Envoyer l'article

Title:

Adverse Analytical Finding for Frank Schleck

Date:

17.07.2012

Description:

Earlier today, the UCI advised the Luxembourger rider Frank Schleck  of  an Adverse Analytical Finding (presence of the diuretic Xipamide based on the report from the WADA accredited laboratory in Châtenay-Malabry) in the urine sample collected from him at an in competition test at the Tour de France on 14 July 2012.

Mr. Schleck has the right to request and attend the analysis of his B sample.

The UCI Anti-Doping Rules do not provide for a provisional suspension given the nature of the substance, which is a specified substance.

However,  the UCI is confident that his team will take the necessary steps to enable the Tour de France to continue in serenity and to ensure that their rider has the opportunity to properly prepare his defense in particular within the legal timeline, which allows four days for him to have his B sample analyzed.

Under the World Anti-Doping Code and the UCI Anti-Doping Rules, the UCI is unable to provide any additional information at this time.

UCI Communications Services

 

Characteristics:
Back
  Publications  Links  Employment  FAQ  Contacts  RSS